U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530926) titled 'Adrenal& Bone Complications in Paediatric Patients Living With Spinal Muscular Atrophy (SMA)' on Nov. 14, 2025.
Brief Summary: Spinal muscular atrophy (SMA) is a genetic disorder that is known to cause damage to specialised nerve cells, called motor neurons. These neurons are located in the spinal cord and transfer signals from the brain to muscles to allow movement. A lack of nerve signalling leads to progressive muscle weakness and wasting, which affects a person' mobility, breathing and swallowing. Treatments have only recently been developed and there are now three commercially available drugs for SMA. These drugs improve survi...